Biocryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases, and cancer. It uses structure-based drug design, which incorporates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals. The company has three novel late-stage compounds in development, which include peramivir, a neuraminidase inhibitor for the treatment of influenza, which is in Phase III clinical trial stage; BCX4208, a Phase II clinical trial stage purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout; and forodesine, an orally-available PNP inhibitor for cancer, which is in Phase II clinical trial stage. Its pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema; and BCX5191, a novel adenine nucleoside analog targeting viral RNA polymerase for the treatment of hepatitis C. The company has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.